CSL Posts 23 Percent Revenue Growth, Boosted Largely By H1N1 Sales
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-headquartered CSL attributed its 23 percent revenue growth for the first half of 2010 to it's A/H1N1 vaccine Panvax out of its Biotherapies business unit. Business strategy for the company will focus on geographic expansion in emerging markets and specialty products
You may also be interested in...
CSL's Seasonal Flu Vaccine Halted In Kids Under 5 Following Spike In Adverse Events In West Australian Children
PERTH, Australia - Australia's Therapeutic Goods Administration is investigating reports of an increase in adverse events tied to CSL's seasonal flu vaccine in Western Australia in children under the age of five
CSL's Seasonal Flu Vaccine Halted In Kids Under 5 Following Spike In Adverse Events In West Australian Children
PERTH, Australia - Australia's Therapeutic Goods Administration is investigating reports of an increase in adverse events tied to CSL's seasonal flu vaccine in Western Australia in children under the age of five
CSL Wins HAE Race For U.S. FDA Approval; Will Orphan Drug Rules Lock The Gate Behind?
PERTH, Australia - CSL Behring, a U.S. subsidiary of the Australian-headquartered CSL Limited, announced U.S. FDA approval Oct. 12 of its C1 esterase inhibitor Berinert for treating adults and adolescents with acute abdominal or facial attacks of hereditary angioedema (HAE)